The effects of dupilumab treatment on general health-related work productivity of adult atopic patients

Napolitano, Maddalena; Fabbrocini, Gabriella; Nocerino, Mariateresa; Potestio, Luca; Patruno, Cataldo

doi:10.23736/s2784-8671.22.07179-1

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sensitivity analyses that accounted for missing values confirmed the robustness of the results. These results also expand on previous reports of the real-world effectiveness of dupilumab by providing a substantially longer follow-up and using a broader range of outcomes relevant to the daily life of patients than studies that mainly focused on clinical measures of disease activity and HRQoL [ 16 – 21 ].…”

Section: Discussionsupporting

confidence: 69%

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study

Kimball

Delevry

Yang

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction Atopic dermatitis (AD) can require long-term therapy. Few real-world studies have evaluated long-term effectiveness from the patients’ perspective. The aim of this study was to evaluate patient-reported outcomes (PROs) during long-term dupilumab treatment. Methods Adults with moderate-to-severe AD who initiated dupilumab through the US manufacturer patient support program and participated in RELIEVE-AD (a prospective patient survey study with a 12-month follow-up) were recontacted 30–36 months post-initiation regardless of current dupilumab use. The online questionnaire consisted of PROs, including the Atopic Dermatitis Control Tool (ADCT), use of concomitant AD therapies, satisfaction with current therapy, global change in itch relative to before dupilumab initiation, non-itch skin symptoms (skin pain/soreness, hot/burning feeling, and sensitivity to touch), flares, Dermatology Life Quality Index, sleep problems, and the AD-specific Work Productivity and Activity Impairment Questionnaire. Results Of 698 patients who initiated dupilumab (baseline) and were recontacted, 425 completed the 30–36-month survey. Significant reductions from baseline were reported in concomitant AD therapy use ( P < 0.05); 54.4% reported not using other AD medications vs. 12.8% at baseline. At 30–36 months, all results (non-itch skin symptoms, flares, sleep problems, health-related quality of life work/activity impairment, disease control, and treatment satisfaction) were similar to or incrementally better than the 12-month timepoint, with significant improvements vs. baseline ( P < 0.001). Global change in itch was reported as “very much better” by 75.3% of respondents. Adequate disease control (score < 7 on ADCT) was reported by 80.7% of respondents, and 86.8% were satisfied with the treatment. Conclusions In clinical practice settings, patient-reported benefits of dupilumab were maintained in survey respondents during long-term treatment up to 36 months while the use of concomitant AD therapies reduced. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-023-00965-5.

show abstract

Section: Discussionsupporting

confidence: 69%

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study

Kimball

Delevry

Yang

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…Furthermore, self-injection of dupilumab at home releases patients from regular visits and improves compliance, 14 and it is beneficial for workers. It has been reported that dupilumab improved work productivity in European AD patients, 15,16 but not in Japanese patients yet. Furthermore, data on the effect of long-term treatment with dupilumab on work productivity are limited.…”

Section: Introductionmentioning

confidence: 88%

Impact of 1‐year treatment with dupilumab on work productivity in Japanese patients with atopic dermatitis

Sakurai,

Kamata,

Uchida

et al. 2024

Experimental Dermatology

View full text Add to dashboard Cite

Atopic dermatitis (AD) places a burden on work productivity. Recently, dupilumab was approved for AD, but its impact on work productivity in Japanese patients has not been reported. Furthermore, data on the effect of long‐term treatment with dupilumab on work productivity are limited. We investigated the work productivity and activity in Japanese patients with moderate‐to‐severe AD, utilizing the Japanese version of the Work Productivity and Activity Impairment (WPAI‐AD‐Japan) questionnaire. Furthermore, we examined the impact of dupilumab on work productivity. Adult moderate‐to‐severe AD patients treated with dupilumab for more than 12 months from March 2020 to June 2022 who filled out the WPAI‐AD‐Japan questionnaire were included. Twenty‐eight adult AD patients were analysed. Absenteeism was low (mean: 5.3%), but presenteeism, work productivity loss and activity impairment were high (36.8%, 39.7%, 48.9%, respectively). Significant positive correlations were observed between work productivity loss and visual analogue scale (VAS) score of pruritus and between activity impairment and dermatology life quality index (DLQI). Dupilumab treatment significantly reduced presenteeism, work productivity loss and activity impairment at both 6 and 12 months. The extent of their amelioration was numerically higher at 12 months than at 6 months. The reduction rates in presenteeism, work productivity loss and activity impairment were positively correlated with the reduction rates in DLQI and VAS score of pruritus at 12 months. Dupilumab improved work productivity in Japanese AD patients. Long‐term remission of pruritus and improved quality of life are important for comprehensive improvement of work productivity.

show abstract

The effects of dupilumab treatment on general health-related work productivity of adult atopic patients

Cited by 2 publications

References 8 publications

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study

Impact of 1‐year treatment with dupilumab on work productivity in Japanese patients with atopic dermatitis

Contact Info

Product

Resources

About